Do it like the immune system: novel antimicrobials

August 30, 2012
Do it like the immune system: novel antimicrobials
© Thinkstock

Microbial infections are becoming unbeatable due to progressive mutations that lead to antimicrobial drug resistance. European scientists exploited the characteristics of novel antimicrobial compounds that mimic the dual activities of natural antimicrobial proteins.

The fight against contagious diseases is seriously threatened by the growing development of antimicrobial-. There is a profound need for novel and diverse antimicrobial prevention and .

Towards this direction, three pathways can be followed for the design of efficient drugs. The first is to target evolutionary conserved regions of the protein targets that have lower possibilities for change and therefore develop . The second is the creation of drugs of multiple activities and targets leading to enhanced antimicrobial action and low resistance development. Finally, the third pathway involves drug cocktails of many active compounds of diverse activities and specificities.

The EU project 'Antimicrobials by immune stimulation' (AMIS) aimed at the design and evaluation of novel antimicrobial drugs that mimic features of human antimicrobial proteins. AMIS scientists combined all three aforementioned approaches in an integrative and innovative manner using the human innate system as a model for new antimicrobial compounds. Since in the comprise different signals in a single molecule, AMIS researchers made novel antimicrobial molecules of combined features.

Initially, AMIS scientists collected and studied the properties of a plethora of promising natural antimicrobial molecules which have been identified in recent years. Taking the information from these studies, they designed antimicrobial proteins with dual activity. These proteins are able, on the one hand, to target extracellular or and, on the other, to weaken inflammation.

Within AMIS, important tools for the evaluation of antimicrobial proteins were optimised and validated. In addition, a variety of new compounds with either antimicrobial or anti-inflammatory activity were discovered.

Importantly, AIMS researchers managed to decipher the exact molecular mechanism of action in some of these compounds, essential for the design of effective drugs. Moreover, the most promising compounds were selected for the creation of fused compounds with even better characteristics. The first fused compound was created and is currently under evaluation.

The AMIS project did not result in a specific therapeutic strategy but it highlighted current limitations in the development of antimicrobial proteins against antimicrobial resistance. The reason for these limitations is not strictly technical but rather a lack of fundamental knowledge in the field of microbial pathogenesis and innate immune system.

Explore further: Antimicrobial resistance for common urinary tract infections drug increases five fold since 2000

More information: Information Source: Result from the EU funded FP6-LIFESCIHEALTH programme

Related Stories

Antimicrobial resistance for common urinary tract infections drug increases five fold since 2000

April 30, 2012
WASHINGTON, District of Columbia (April 30, 2012) – In a surveillance study of over 12 million bacteria, investigators at The George Washington University and Providence Hospital found E. coli antimicrobial resistance ...

EU sounds cry of alarm over resistance to antibiotics

November 17, 2011
The European Union warned Thursday of a sharp rise in deaths across the 27-nation bloc due to bacteria becoming resistant to antibiotics.

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.